GH Research (NASDAQ:GHRS) Stock Price Up 3.9%

GH Research PLC (NASDAQ:GHRS)’s stock price rose 3.9% on Tuesday . The stock traded as high as $11.17 and last traded at $11.17. Approximately 25,068 shares were traded during mid-day trading, a decline of 80% from the average daily volume of 127,582 shares. The stock had previously closed at $10.75.

Analysts Set New Price Targets

GHRS has been the subject of several recent research reports. JMP Securities cut their price target on GH Research from $50.00 to $39.00 and set a “market outperform” rating for the company in a report on Friday, March 1st. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of GH Research in a report on Monday, March 4th.

GH Research Price Performance

The business has a 50-day simple moving average of $10.07 and a 200-day simple moving average of $7.91.

GH Research (NASDAQ:GHRS) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). As a group, equities research analysts expect that GH Research PLC will post -0.96 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. BVF Inc. IL raised its holdings in shares of GH Research by 12.1% in the fourth quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock valued at $60,321,000 after buying an additional 1,125,000 shares during the last quarter. RTW Investments LP increased its position in GH Research by 53.4% during the 3rd quarter. RTW Investments LP now owns 3,327,129 shares of the company’s stock worth $33,438,000 after purchasing an additional 1,158,172 shares during the period. Lynx1 Capital Management LP raised its stake in shares of GH Research by 13.8% during the 3rd quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company’s stock worth $11,087,000 after buying an additional 133,804 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in GH Research by 14.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 106,363 shares of the company’s stock worth $617,000 after acquiring an additional 13,579 shares during the period. Finally, Barclays PLC lifted its holdings in GH Research by 98.2% in the third quarter. Barclays PLC now owns 63,590 shares of the company’s stock valued at $640,000 after acquiring an additional 31,500 shares during the period. Institutional investors and hedge funds own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).